IN & OUT
Merck’s Udit Batra receives ‘CEO of the Year’ Award from CPhI Pharma
CEO of Merck’s life science business, Udit Batra, was named “CEO of the Year” for 2016 by CPhI Pharma for his commitment to furthering life science innovation globally.
Udit Batra announces:
“As advances in drug discovery yield more complex therapies, drug development and manufacturing must innovate at even a faster pace. At Merck, we will continue to empower researchers and scientists with solutions that improve drug development quality and efficiency, helping them solve their toughest problems. On behalf of Merck, I am honored to receive this award.”
Nouscom appoints Marina Udier Blagovic as new COO
Marina Udier Blagovic is the new Chief Operating Officer of the Swiss company Nouscom. The new position has been created to drive all aspects of business operations and business development. Marina Udier Blagovic joins Nouscom from Versant Ventures where she was an Operating Principal. Prior to Versant, she was the Global Head of Neurodegeneration at Novartis where she managed blockbuster brands. Her experience in oncology includes the development of a companion diagnostics. She has a Ph.D. in Organic Chemistry from Yale University.
The Company also appointed a new Board Directors who will join Dr. Guido Magni and Joachim Rothe: Dr Jean-Paul Prieels will join as Non-Executive Director; Dr Vincent Brichard and Dr Gianni Gromo will join as Board Observers.
Sanofi appoints Alan Main as EVP, consumer healthcare
Sanofi has appointed Alan Main as Executive Vice President, consumer healthcare. Main will be a member of the executive committee and lead a newly created consumer healthcare global business unit. Main will also be responsible for building and maintaining Sanofi’s position in consumer healthcare. Main has more than 30 years of marketing and general management experience in the consumer health and medical device fields.
GSK has appointed Brian McNamara as CEO of the healthcare division
GlaxoSmithKline has appointed Brian McNamara as chief executive officer (CEO) of GSK’s consumer healthcare division. He succeeds Emma Walmsley who has recently been appointed as GSK CEO. McNamara, currently head of Europe & Americas at GSK consumer healthcare, will continue as a member of the board of the Consumer Healthcare Joint Venture with Novartis. Prior to joining GSK, he spent 11 years at Novartis and 16 years at Procter & Gamble.
Mario Melazzini is the new General Manager at AIFA (The Italian Medicines Agency)
The Italian Medicines Agency has a new General Manager.
His name is Mario Melazzini, already President of the Agency.
Melazzini, who takes over from Luca Pani, is a Medical Doctor specialized in Emathology and is a Resercher in the onco-ematholovical filed.
Cognition Therapeutics appointed Kenneth I. Moch President and CEO
Cognition Therapeutics has a new President and Chief Executive Officer.
He is Kenneth Moch, that will also join the company’s Board of Directors. Prior to joining Cognition, Moch has been a Managing Partner of The Salutramed Group.
He has also been a Managing Director, Healthcare Banking at ThinkEquity Partners and a management consultant with McKinsey & Company, Inc.
Mr. Moch succeeds Hank Safferstein, who will remain with Cognition in an executive leadership capacity.
ERYTECH appoints new CSO and CBO
Alexander Scheer is the new Chief Scientific Officer and Jean-Sébastien Cleiftie will serve as Chief Business Officer at Erytech Pharma, the French biopharma company developing ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs.
Alexander Scheer announces:
“We are delighted to welcome Alexander and Jean-Sébastien to the Erytech leadership team as they both bring invaluable experience from cross-functional areas of the life science industry,” commented Gil Beyen, CEO and Chairman of the Board. “Alexander brings a wealth of knowledge in leading global R&D and drug discovery across multiple disciplines and several therapeutic areas, while Jean-Sébastien’s deep expertise in biopharmaceutical business development and financial valuation will be instrumental to Erytech as we continue to diversify our programs and address unmet medical needs of patients.”
Roberto Tascione new Ceo of Zambon
Zambon has appointed Roberto Tascione as new CEO to drive the business on a global scale.
Tascione, 54 years, has a long experience in the pharmaceutical sector and started his career at Bristol Myers Squibb Italy, before leading the Primary Care and OTC divisions of Schering Plough. From 2009 to 2014 he was CEO of Gilead Italy and on May 2014 he returned to Bristol Myers Squibb as President and Chief Executive Officer Italy.
Alexander Scheer announces:
“Zambon is a leading Italian excellence, with a strong tradition and a strong international outlook dating back to the ‘50s- said Tascione- I share the same values and I am very proud to drive the company in this new stage of growth, look at new business opportunities and strengthen our international network. I have accepted this new role with great enthusiasm and commitment “.
Biogen Announces Additional Members of Management Team of Hemophilia Spin-off Company Bioverativ
Biogen will add two members to the executive management team of Bioverativ Inc., Biogen’s planned spin-off company focused on the discovery, research, development and commercialization of treatments for hemophilia and other blood disorders. Rogerio Vivaldi, M.D., will serve as executive vice president and chief global therapeutic operations officer of Bioverativ, and John T. Greene will serve as executive vice president and chief financial officer of Bioverativ. The spin-off of Bioverativ is on track to be completed in early 2017.
GlaxoSmithKline has appointed Emma Walmsley as new CEO
Emma Walmsley has been named as the new GlaxoSmithKline’s CEO.
Married, mother of 4 sons, and fond of yoga, Walmsley will be effective in spring when the actual CEO, Sir Andrew Wittey will retired.
Prior to joining GSK, Walmset has served L’Oreal for 17 years, in the Marketing Department.
Newsroom’s selection - Final copy approved on December 15th, 2016.